NEW YORK (GenomeWeb News) – Cancer Genetics today reported that its second quarter revenues increased 64 percent year over year.

For the three months ended June 30, revenues rose to $1.8 million, up from $1.1 million. Clinical test volume increased 97 percent to 3,204 tests during the recently completed quarter, compared to 1,623 a year ago, Cancer Genetics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.